Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T17:58:16.206Z.
Calculation as of: 2026-10-06T17:58:16.206Z.
Quote observation: 2026-10-06T17:55:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bc1f4c18f19876ab16fbc38bb33c2f59d02ebf5b777874ee4386cd5e587f8fe3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
SOPHiA GENETICS S.A.
Market Cap
$634.15M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$634.07M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$639.31M
Operating Cash Flow Yield
N/A
TTM Avg
2.08%
3Y Avg
1.21%
5Y Avg
1.21%
Market Cap
$629.45M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$615.86M
Operating Cash Flow Yield
N/A
TTM Avg
0.02%
3Y Avg
0.02%
5Y Avg
0.02%
Market Cap
$657.51M
Operating Cash Flow Yield
0.05%
TTM Avg
0.05%
3Y Avg
0.05%
5Y Avg
0.05%
Market Cap
$666.78M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$668.50M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $634.15M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $634.07M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $639.31M | N/A | 2.08% | 1.21% | 1.21% |
| Prime Medicine, Inc. (PRME)vs › | $629.45M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $615.86M | N/A | 0.02% | 0.02% | 0.02% |
| Starling Oncology, Inc. (STLN)vs › | $657.51M | 0.05% | 0.05% | 0.05% | 0.05% |
| Annexon, Inc. (ANNX)vs › | $664.38M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $666.78M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $668.50M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.82M | 30.88% | 16.53% | 24.40% | 19.97% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
